Bioline Rx Ltd Adr stock is traded at $1.74, with a volume of 4,123. It is down -1.38% in the last 24 hours and down -23.93% over the past month. BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Previous Close:
$1.77
Open:
$1.72
24h Volume:
4,123
Relative Volume:
0.56
Market Cap:
$8.68M
Revenue:
$1.41M
Net Income/Loss:
-$9.84M
P/E Ratio:
-
EPS:
-$2.14
Net Cash Flow:
-$7.85M
1W Performance:
-12.38%
1M Performance:
-23.93%
6M Performance:
-47.95%
1Y Performance:
-47.64%
1-Day Range:
$1.71$1.74
1-Week Range:
$1.70$1.99
52-Week Range:
$1.70$3.95
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS